Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Shenzhen Neptunus Bioengineering Files for US Test of TCM

publication date: Jan 18, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shenzhen Neptunus Bioengineering announced that it has filed an application for a US Phase II clinical trial of Polydatin Injection. Polydatin is a Class I innovative traditional Chinese medicine that aides microcirculation of the blood and is expected to be tested as a treatment for myocardial ischemia, cerebral ischemia, shock and other cardiovascular diseases. More details....

Stock Symbol: (SHE: 000078)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
ChinaBio® Events
Shanghai, China
April 14-15, 2015

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors